← Back to directory
AV
ARCH Venture Partners
Chicago, Illinois, U.S.Website ↗
ARCH Venture Partners is a leading venture capital firm specializing in early-stage investments in life sciences and technology, focusing on groundbreaking innovations that aim to transform healthcare and biotech. They are known for co-founding and building breakthrough deep science companies with university researchers and scientists, providing patient capital from concept stage through commercialization.
Last raised
Sep 2024
1y 9mo ago
Latest fund size
$3B
ARCH Venture Fund XIII
AUM
$12B
estimated
Funds raised
Capital this firm has raised, newest first
ARCH Venture Fund VII
Unknown · Fund VII
$1B
ARCH Venture Fund XIII
Sep 2024 · Fund XIII
$3B
ARCH Venture Fund XII
Jun 2022 · Fund XII
$3B
ARCH Venture Fund XI
Jan 2020 · Fund XI
—
ARCH Venture Fund Limited Partnership
Jan 1989
$9M
Recent investments
Companies this firm has funded, newest first
| Company | Round | Amount | Date | Source |
|---|---|---|---|---|
| CREATE Medicines | Series B | — | Jan 2026 | |
| Moleculent | — | — | Jan 2026 | |
| Maze Therapeutics | Growth | — | Jan 2026 | |
| Lightcast Discovery | — | — | Jan 2026 | |
| Kardigan | Series B | $254M | Jan 2025 | |
| Seaport Therapeutics | — | — | Oct 2024 | |
| Metsera | — | — | Aug 2024 | |
| Xaira TherapeuticsLead | Growth | $1B | Jan 2024 |
Sources
Where this data came from